<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39456219</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2218-273X</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>11</Day></PubDate></JournalIssue><Title>Biomolecules</Title><ISOAbbreviation>Biomolecules</ISOAbbreviation></Journal><ArticleTitle>Validation of the Enzyme-Linked ImmunoSpot Analytic Method for the Detection of Human IFN-γ from Peripheral Blood Mononuclear Cells in Response to the SARS-CoV-2 Spike Protein.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1286</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/biom14101286</ELocationID><Abstract><AbstractText>COVID-19 vaccine evaluations are mainly focused on antibody analyses, but there is growing interest in measuring the cellular immune responses from the researchers evaluating these vaccines. The cellular responses to several COVID-19 vaccines have been studied using the enzyme-linked immunospot (ELISPOT) assay for IFN-γ. However, the ELISPOT assay is no longer used only for research purpose and so the performance of this assay must be validated. Since the bioanalytical validation of ELISPOT-IFN-γ is essential for evaluating the method's effectiveness and establishing confidence in a vaccine's immunogenicity, the present work validates the ELISPOT-IFN-γ assay's performance in determining the frequency of IFN-γ-producing cells after stimulation with the SARS-CoV-2 spike protein. The validation was performed in peripheral blood mononuclear cells from volunteers immunized with anti-COVID-19 vaccines. According to the findings, the LOD was 17 SFU and the LLOQ was 22 SFU, which makes the method highly sensitive and suitable for evaluating low levels of cellular responses. The procedure's accuracy is confirmed by the correlation coefficients for the spike protein and anti-CD3<sup>+</sup>, being 0.98 and 0.95, respectively. The repeatability and intermediate precision tests were confirmed to be reliable by obtaining a coefficient of variation of ≤25%. The results obtained in this validation enable the assay to be employed for studying antigen-specific cells and evaluating cellular responses to vaccines.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Carreto-Binaghi</LastName><ForeName>Laura E</ForeName><Initials>LE</Initials><AffiliationInfo><Affiliation>Laboratorio de Inmunobiología de la Tuberculosis, Instituto Nacional de Enfermedades Respiratorias (INER) Ismael Cosío Villegas, Mexico City 14080, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nieto-Ponce</LastName><ForeName>Milton</ForeName><Initials>M</Initials><Identifier Source="ORCID">0009-0002-3846-3097</Identifier><AffiliationInfo><Affiliation>Laboratorio de Inmunobiología de la Tuberculosis, Instituto Nacional de Enfermedades Respiratorias (INER) Ismael Cosío Villegas, Mexico City 14080, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palencia-Reyes</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0005-3264-3785</Identifier><AffiliationInfo><Affiliation>Laboratorio de Inmunobiología de la Tuberculosis, Instituto Nacional de Enfermedades Respiratorias (INER) Ismael Cosío Villegas, Mexico City 14080, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chávez-Domínguez</LastName><ForeName>Rodolfo L</ForeName><Initials>RL</Initials><Identifier Source="ORCID">0000-0002-4097-6011</Identifier><AffiliationInfo><Affiliation>Laboratorio de Inmunobiología de la Tuberculosis, Instituto Nacional de Enfermedades Respiratorias (INER) Ismael Cosío Villegas, Mexico City 14080, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blancas-Zaragoza</LastName><ForeName>Jessica</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Laboratorio de Inmunobiología de la Tuberculosis, Instituto Nacional de Enfermedades Respiratorias (INER) Ismael Cosío Villegas, Mexico City 14080, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franco-Mendoza</LastName><ForeName>Pablo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Laboratorio de Inmunobiología de la Tuberculosis, Instituto Nacional de Enfermedades Respiratorias (INER) Ismael Cosío Villegas, Mexico City 14080, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>García-Ramos</LastName><ForeName>Montserrat A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Laboratorio de Inmunobiología de la Tuberculosis, Instituto Nacional de Enfermedades Respiratorias (INER) Ismael Cosío Villegas, Mexico City 14080, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hernández-Lázaro</LastName><ForeName>Claudia I</ForeName><Initials>CI</Initials><AffiliationInfo><Affiliation>Laboratorio Clinico, Instituto Nacional de Enfermedades Respiratorias (INER) "Ismael Cosío Villegas", Mexico City 14080, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torres</LastName><ForeName>Martha</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratorio de Inmunobiología de la Tuberculosis, Instituto Nacional de Enfermedades Respiratorias (INER) Ismael Cosío Villegas, Mexico City 14080, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carranza</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-6226-6056</Identifier><AffiliationInfo><Affiliation>Laboratorio de Inmunobiología de la Tuberculosis, Instituto Nacional de Enfermedades Respiratorias (INER) Ismael Cosío Villegas, Mexico City 14080, Mexico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>C53-21</GrantID><Agency>Instituto Nacional de Enfermedades Respiratorias</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D023361">Validation Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Biomolecules</MedlineTA><NlmUniqueID>101596414</NlmUniqueID><ISSNLinking>2218-273X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>82115-62-6</RegistryNumber><NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="Y">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007963" MajorTopicYN="Y">Leukocytes, Mononuclear</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058501" MajorTopicYN="Y">Enzyme-Linked Immunospot Assay</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007371" MajorTopicYN="Y">Interferon-gamma</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Elispot</Keyword><Keyword MajorTopicYN="N">IFN-γ</Keyword><Keyword MajorTopicYN="N">SARS-CoV2</Keyword><Keyword MajorTopicYN="N">immune response</Keyword><Keyword MajorTopicYN="N">validation</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39456219</ArticleId><ArticleId IdType="pmc">PMC11506497</ArticleId><ArticleId IdType="doi">10.3390/biom14101286</ArticleId><ArticleId IdType="pii">biom14101286</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Miao G., Chen Z., Cao H., Wu W., Chu X., Liu H., Zhang L., Zhu H., Cai H., Lu X., et al. From Immunogen to COVID-19 vaccines: Prospects for the post-pandemic era. Biomed. Pharmacother. 2023;158:114208. doi: 10.1016/j.biopha.2022.114208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2022.114208</ArticleId><ArticleId IdType="pmc">PMC9805901</ArticleId><ArticleId IdType="pubmed">36800265</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian J., Zhang S., Wang F., Li J., Zhang J. What makes SARS-CoV-2 unique? Focusing on the spike protein. Cell Biol. Int. 2024;48:404–430. doi: 10.1002/cbin.12130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cbin.12130</ArticleId><ArticleId IdType="pubmed">38263600</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson C.B., Farzan M., Chen B., Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat. Rev. Mol. Cell Biol. 2022;23:3–20. doi: 10.1038/s41580-021-00418-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41580-021-00418-x</ArticleId><ArticleId IdType="pmc">PMC8491763</ArticleId><ArticleId IdType="pubmed">34611326</ArticleId></ArticleIdList></Reference><Reference><Citation>Plotkin S.A. Correlates of Protection Induced by Vaccination. Clin. Vaccine Immunol. 2010;17:1055–1065. doi: 10.1128/CVI.00131-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.00131-10</ArticleId><ArticleId IdType="pmc">PMC2897268</ArticleId><ArticleId IdType="pubmed">20463105</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherman A.C., Desjardins M., Baden L.R. Vaccine-Induced Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response and the Path to Acceleratisng Development (Determining a Correlate of Protection) Clin. Lab. Med. 2022;42:111–128. doi: 10.1016/j.cll.2021.10.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cll.2021.10.008</ArticleId><ArticleId IdType="pmc">PMC8563351</ArticleId><ArticleId IdType="pubmed">35153045</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi W.-Y., Li Y.-D., Huang H.-C., Chan T.E.H., Chow S.-Y., Su J.-H., Ferrall L., Hung C.-F., Wu T.-C. COVID-19 vaccine update: Vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection. J. Biomed. Sci. 2022;29:82. doi: 10.1186/s12929-022-00853-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-022-00853-8</ArticleId><ArticleId IdType="pmc">PMC9569411</ArticleId><ArticleId IdType="pubmed">36243868</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L., Wang P., Nair M.S., Yu J., Rapp M., Wang Q., Luo Y., Chan J.F.-W., Sahi V., Figueroa A., et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature. 2020;584:450–456. doi: 10.1038/s41586-020-2571-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2571-7</ArticleId><ArticleId IdType="pubmed">32698192</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J., Chandrashekar A., Sellers D., Barrett J., Jacob-Dolan C., Lifton M., McMahan K., Sciacca M., VanWyk H., Wu C., et al. Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron. Nature. 2022;603:493–496. doi: 10.1038/s41586-022-04465-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04465-y</ArticleId><ArticleId IdType="pmc">PMC8930761</ArticleId><ArticleId IdType="pubmed">35102312</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon S.-W., Widyasari K., Jang J., Lee S., Kang T., Kim S. Kinetics of adaptive immune responses after administering mRNA-Based COVID-19 vaccination in individuals with and without prior SARS-CoV-2 infections. BMC Infect. Dis. 2023;23:732. doi: 10.1186/s12879-023-08728-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-023-08728-5</ArticleId><ArticleId IdType="pmc">PMC10604405</ArticleId><ArticleId IdType="pubmed">37891503</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z., Mateus J., Coelho C.H., Dan J.M., Moderbacher C.R., Gálvez R.I., Cortes F.H., Grifoni A., Tarke A., Chang J., et al. Humoral and cellular immune memory to four COVID-19 vaccines. Cell. 2022;185:2434–2451.e17. doi: 10.1016/j.cell.2022.05.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.05.022</ArticleId><ArticleId IdType="pmc">PMC9135677</ArticleId><ArticleId IdType="pubmed">35764089</ArticleId></ArticleIdList></Reference><Reference><Citation>Bercovici N., Duffour M.-T., Agrawal S., Salcedo M., Abastado J.-P. New Methods for Assessing T-Cell Responses. Clin. Diagn. Lab. Immunol. 2000;7:859–864. doi: 10.1128/CDLI.7.6.859-864.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CDLI.7.6.859-864.2000</ArticleId><ArticleId IdType="pmc">PMC95974</ArticleId><ArticleId IdType="pubmed">11063487</ArticleId></ArticleIdList></Reference><Reference><Citation>Leehan K.M., Koelsch K.A. T Cell ELISPOT: For the Identification of Specific Cytokine-Secreting T Cells. In: Kurien B.T., Scofield R.H., editors. Western Blotting. Volume 1312. Springer; New York, NY, USA: 2015. pp. 427–434. Methods in Molecular Biology.</Citation><ArticleIdList><ArticleId IdType="pubmed">26044024</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C., Yang S., Duan L., Du X., Tao J., Wang Y., Yang J., Lv Y., Li J., Zhang C., et al. Adaptive immune responses and cytokine immune profiles in humans following prime and boost vaccination with the SARS-CoV-2 CoronaVac vaccine. Virol. J. 2022;19:223. doi: 10.1186/s12985-022-01957-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-022-01957-1</ArticleId><ArticleId IdType="pmc">PMC9774075</ArticleId><ArticleId IdType="pubmed">36550578</ArticleId></ArticleIdList></Reference><Reference><Citation>Slota M., Lim J.-B., Dang Y., Disis M.L. ELISpot for measuring human immune responses to vaccines. Expert Rev. Vaccines. 2011;10:299–306. doi: 10.1586/erv.10.169.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/erv.10.169</ArticleId><ArticleId IdType="pmc">PMC3360522</ArticleId><ArticleId IdType="pubmed">21434798</ArticleId></ArticleIdList></Reference><Reference><Citation>Streeck H., Frahm N., Walker B.D. The role of IFN-γ Elispot assay in HIV vaccine research. Nat. Protoc. 2009;4:461–469. doi: 10.1038/nprot.2009.7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2009.7</ArticleId><ArticleId IdType="pubmed">19282851</ArticleId></ArticleIdList></Reference><Reference><Citation>Boaz M.J., Hayes P., Tarragona T., Seamons L., Cooper A., Birungi J., Kitandwe P., Semaganda A., Kaleebu P., Stevens G., et al. Concordant Proficiency in Measurement of T-Cell Immunity in Human Immunodeficiency Virus Vaccine Clinical Trials by Peripheral Blood Mononuclear Cell and Enzyme-Linked Immunospot Assays in Laboratories from Three Continents. Clin. Vaccine Immunol. 2009;16:147–155. doi: 10.1128/CVI.00326-08.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.00326-08</ArticleId><ArticleId IdType="pmc">PMC2643552</ArticleId><ArticleId IdType="pubmed">19091991</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagenhäuser I., Almanzar G., Förg F.B., Stein A., Eiter I., Reusch J., Mees J., Herzog A., Vogel U., Frey A., et al. Heterologous and homologous COVID-19 mRNA vaccination schemes for induction of basic immunity show similar immunogenicity regarding long-term spike-specific cellular immunity in healthcare workers. Vaccine. 2024;42:126132. doi: 10.1016/j.vaccine.2024.07.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2024.07.033</ArticleId><ArticleId IdType="pubmed">39034219</ArticleId></ArticleIdList></Reference><Reference><Citation>Konuma T., Hamatani-Asakura M., Nagai E., Adachi E., Kato S., Isobe M., Monna-Oiwa M., Takahashi S., Yotsuyanagi H., Nannya Y. Cellular and humoral immunogenicity against SARS-CoV-2 vaccination or infection is associated with the memory phenotype of T- and B-lymphocytes in adult allogeneic hematopoietic cell transplant recipients. Int. J. Hematol. 2024;120:229–240. doi: 10.1007/s12185-024-03802-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12185-024-03802-3</ArticleId><ArticleId IdType="pmc">PMC11284193</ArticleId><ArticleId IdType="pubmed">38842630</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreasson U., Perret-Liaudet A., Van Waalwijk Van Doorn L.J.C., Blennow K., Chiasserini D., Engelborghs S., Fladby T., Genc S., Kruse N., Kuiperij H.B., et al. A Practical Guide to Immunoassay Method Validation. Front. Neurol. 2015;6:179. doi: 10.3389/fneur.2015.00179.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2015.00179</ArticleId><ArticleId IdType="pmc">PMC4541289</ArticleId><ArticleId IdType="pubmed">26347708</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J.W., Devanarayan V., Barrett Y.C., Weiner R., Allinson J., Fountain S., Keller S., Weinryb I., Green M., Duan L., et al. Fit-for-Purpose Method Development and Validation for Successful Biomarker Measurement. Pharm. Res. 2006;23:312–328. doi: 10.1007/s11095-005-9045-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11095-005-9045-3</ArticleId><ArticleId IdType="pubmed">16397743</ArticleId></ArticleIdList></Reference><Reference><Citation>Malyguine A.M., Strobl S., Dunham K., Shurin M.R., Sayers T.J. ELISPOT Assay for Monitoring Cytotoxic T Lymphocytes (CTL) Activity in Cancer Vaccine Clinical Trials. Cells. 2012;1:111–126. doi: 10.3390/cells1020111.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells1020111</ArticleId><ArticleId IdType="pmc">PMC3901085</ArticleId><ArticleId IdType="pubmed">24710418</ArticleId></ArticleIdList></Reference><Reference><Citation>Carranza C., Juárez E., Torres M., Ellner J.J., Sada E., Schwander S.K. Mycobacterium tuberculosis Growth Control by Lung Macrophages and CD8 Cells from Patient Contacts. Am. J. Respir. Crit. Care Med. 2006;173:238–245. doi: 10.1164/rccm.200503-411OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.200503-411OC</ArticleId><ArticleId IdType="pmc">PMC2662991</ArticleId><ArticleId IdType="pubmed">16210664</ArticleId></ArticleIdList></Reference><Reference><Citation>Vivekanandan M.M., Adankwah E., Aniagyei W., Acheampong I., Minadzi D., Yeboah A., Arthur J.F., Lamptey M., Abass M.K., Kumbel F., et al. Impaired T-cell response to phytohemagglutinin (PHA) in tuberculosis patients is associated with high IL-6 plasma levels and normalizes early during anti-mycobacterial treatment. Infection. 2023;51:1013–1023. doi: 10.1007/s15010-023-01977-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-023-01977-1</ArticleId><ArticleId IdType="pmc">PMC10352402</ArticleId><ArticleId IdType="pubmed">36650358</ArticleId></ArticleIdList></Reference><Reference><Citation>Pérez-Barrios Y., Aranguren-Mazorra Y., Zayas-Vignier C., Blain-Torres K., Hernández-Cedeño M., Rodríguez-Hernández Y., Álvarez-Tito M., Nuñez-Martínez D., González-Aznar E., Soubal-Mora J.P., et al. Estandarización de un ELISA para la cuantificación de anticuerpos IgG contra vesículas de membrana externa de Salmonella Paratyphi A. Vaccimonitor. 2018;27:76–83.</Citation></Reference><Reference><Citation>Corsaro B., Yang T., Murphy R., Sonderegger I., Exley A., Bertholet S., Dakappagari N., Dessy F., Garofolo F., Kierstead L., et al. 2020 White Paper on Recent Issues in Bioanalysis: Vaccine Assay Validation, qPCR Assay Validation, QC for CAR-T Flow Cytometry, NAb Assay Harmonization and ELISpot Validation (Part 3 –Recommendations on Immunogenicity Assay Strategies, NAb Assays, Biosimilars and FDA/EMA Immunogenicity Guidance/Guideline, Gene &amp; Cell Therapy and Vaccine Assays) Bioanalysis. 2021;13:415–463. doi: 10.4155/bio-2021-0007.</Citation><ArticleIdList><ArticleId IdType="doi">10.4155/bio-2021-0007</ArticleId><ArticleId IdType="pubmed">33533276</ArticleId></ArticleIdList></Reference><Reference><Citation>Islam R., Vance J., Poirier M., Zimmer J., Khadang A., Williams D., Zemo J., Lester T., Fjording M., Hays A., et al. Recommendations on ELISpot Assay Validation by the GCC. Bioanalysis. 2022;14:187–193. doi: 10.4155/bio-2022-0010.</Citation><ArticleIdList><ArticleId IdType="doi">10.4155/bio-2022-0010</ArticleId><ArticleId IdType="pubmed">35135309</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng Y., Li Y., Yang R., Tan W. SARS-CoV-2-specific T cell immunity to structural proteins in inactivated COVID-19 vaccine recipients. Cell Mol. Immunol. 2021;18:2040–2041. doi: 10.1038/s41423-021-00730-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-021-00730-8</ArticleId><ArticleId IdType="pmc">PMC8280564</ArticleId><ArticleId IdType="pubmed">34267334</ArticleId></ArticleIdList></Reference><Reference><Citation>Janetzki S., Rueger M., Dillenbeck T. Stepping up ELISpot: Multi-Level Analysis in FluoroSpot Assays. Cells. 2014;3:1102–1115. doi: 10.3390/cells3041102.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells3041102</ArticleId><ArticleId IdType="pmc">PMC4276915</ArticleId><ArticleId IdType="pubmed">25437440</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmittel A., Keilholz U., Scheibenbogen C. Evaluation of the interferon-γ ELISPOT-assay for quantification of peptide specific T lymphocytes from peripheral blood. J. Immunol. Methods. 1997;210:167–174. doi: 10.1016/S0022-1759(97)00184-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-1759(97)00184-1</ArticleId><ArticleId IdType="pubmed">9520299</ArticleId></ArticleIdList></Reference><Reference><Citation>Tary-Lehmann M., Hamm C.D., Lehmann P.V. Validating Reference Samples for Comparison in a Regulated ELISPOT Assay. In: Prabhakar U., Kelley M., editors. Validation of Cell-Based Assays in the GLP Setting. Wiley; Hoboken, NJ, USA: 2008. pp. 127–146.</Citation></Reference><Reference><Citation>Samri A., Durier C., Urrutia A., Sanchez I., Gahery-Segard H., Imbart S., Sinet M., Tartour E., Aboulker J.-P., Autran B., et al. Evaluation of the Interlaboratory Concordance in Quantification of Human Immunodeficiency Virus-Specific T Cells with a Gamma Interferon Enzyme-Linked Immunospot Assay. Clin. Vaccine Immunol. 2006;13:684–697. doi: 10.1128/CVI.00387-05.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.00387-05</ArticleId><ArticleId IdType="pmc">PMC1489560</ArticleId><ArticleId IdType="pubmed">16760328</ArticleId></ArticleIdList></Reference><Reference><Citation>Waerlop G., Leroux-Roels G., Lambe T., Bellamy D., Medaglini D., Pettini E., Cox R.J., Trieu M.-C., Davies R., Bredholt G., et al. Harmonization and qualification of an IFN-γ Enzyme-Linked ImmunoSpot assay (ELISPOT) to measure influenza-specific cell-mediated immunity within the FLUCOP consortium. Front. Immunol. 2022;13:984642. doi: 10.3389/fimmu.2022.984642.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.984642</ArticleId><ArticleId IdType="pmc">PMC9493492</ArticleId><ArticleId IdType="pubmed">36159843</ArticleId></ArticleIdList></Reference><Reference><Citation>Körber N., Behrends U., Hapfelmeier A., Protzer U., Bauer T. Validation of an IFNγ/IL2 FluoroSpot assay for clinical trial monitoring. J. Transl. Med. 2016;14:175. doi: 10.1186/s12967-016-0932-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-016-0932-7</ArticleId><ArticleId IdType="pmc">PMC4906590</ArticleId><ArticleId IdType="pubmed">27297580</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H., Sun J., Li Y., Duan W.-M., Bi J., Qu T. Human umbilical cord-derived mesenchymal stem cells suppress proliferation of PHA-activated lymphocytes in vitro by inducing CD4+CD25highCD45RA+ regulatory T cell production and modulating cytokine secretion. Cell. Immunol. 2016;302:26–31. doi: 10.1016/j.cellimm.2016.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellimm.2016.01.002</ArticleId><ArticleId IdType="pubmed">26774852</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W., Caspell R., Karulin A.Y., Ahmad M., Haicheur N., Abdelsalam A., Johannesen K., Vignard V., Dudzik P., Georgakopoulou K., et al. ELISPOT assays provide reproducible results among different laboratories for T-cell immune monitoring--even in hands of ELISPOT-inexperienced investigators. J. Immunotoxicol. 2009;6:227–234. doi: 10.3109/15476910903317546.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/15476910903317546</ArticleId><ArticleId IdType="pubmed">19908941</ArticleId></ArticleIdList></Reference><Reference><Citation>Ponce-de-León S., Torres M., Soto-Ramírez L.E., Calva J.J., Santillán-Doherty P., Carranza-Salazar D.E., Carreño J.M., Carranza C., Juárez E., Carreto-Binaghi L.E., et al. Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico. NPJ Vaccines. 2023;8:67. doi: 10.1038/s41541-023-00662-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-023-00662-6</ArticleId><ArticleId IdType="pmc">PMC10170424</ArticleId><ArticleId IdType="pubmed">37164959</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>